Australia's groundbreaking newborn screening could slash rare disease diagnosis times

A large-scale pilot study is now screening Australian newborns for four rare genetic disorders. The project aims to speed up diagnoses that often take years, reducing the wait to just weeks. Researchers hope the new test will soon become standard in hospitals worldwide. The study focuses on Angelman, Prader-Willi, Fragile X, and Dup15q syndromes. Around 75,000 babies will be tested using the MS-QMA method, developed by David Godler, an associate professor at Murdoch Children’s Research Institute. This same test is also being trialled on 100,000 additional samples, funded by the Australian National Medical Research Council and the Medical Research Future Fund.

Current estimates suggest Angelman and Prader-Willi syndromes affect between one in 12,000 and one in 30,000 live births. The study seeks to provide clearer data on how often these conditions occur. Funding comes from the Victorian Medical Research Acceleration Fund, the Angelman Syndrome Foundation, and the Foundation for Prader-Willi Research. Eileen Braun, executive director of the Angelman Syndrome Foundation, believes the test could cut diagnosis times from years to weeks. Theresa Strong, director of research programs at FPWR, expects the pilot to prove the tool’s reliability for broader use. Jessica Duis, who leads clinics for these syndromes at Vanderbilt University, argues that early detection will improve patient outcomes. Godler’s goal is to integrate the MS-QMA test into routine newborn screenings globally. If successful, the method could transform how rare genetic disorders are identified and managed from birth.

The pilot study marks a major step toward faster, more accurate diagnoses for rare syndromes. Results will determine whether the MS-QMA test can be adopted in hospitals worldwide. For now, researchers and advocates are watching closely as the screening of 75,000 newborns gets underway.